Greenwich LifeSciences (NASDAQ: GLSI) Reports Higher Patient Screening Rate in FLAMINGO-01 Trial
Expert Analysis Greenwich LifeSciences (NASDAQ: GLSI) continues to demonstrate progress within its Phase III clinical trial framework by focusing on the FLAMINGO-01 study, which evaluates the immunotherapy candidate GLSI-100. As a Fast Track designated treatment aimed at preventing breast cancer recurrence, the increased patient screen rate highlights the growing potential impact of this therapeutic development. This progress could be indicative of positive momentum in patient recruitment and trial execution for…








